Deals · Updated 27 Oct, 08:44 pm IST
Swiss AI drug‑trial startup Atlast Bio raises $12.5M led by Creandum
Why it matters for readers: It explains how AI might run virtual patients to test drugs faster and across multiple diseases.
- Atlast Bio received $12.5 million in funding led by Swedish VC firm Creandum.1
- The company says an AI foundation model trained on about two million human RNA readouts would replace Phase II and animal testing with 12‑week simulations.1
- Atlast Bio aims to replace Phase II drug trials, which it says cost more than $100 million, take two to three years and see about 70% of drugs fail.1
- The startup expects results from a first virtual trial within six weeks and says virtual trials can evaluate drugs across multiple diseases simultaneously.1
- Atlast Bio was founded by former Google employees alongside AI and pharmaceutical specialists.1
Get a brief like this every morning
Uzha reads hundreds of sources and gives you the stories that matter for your work, with every source linked. Free.
Get started